Melinta therapeutics, inc. /new/ (MLNT)
CashFlow / Quarterly
Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Mar'12
Operating activities
Net loss

-213,382

-36,180

-26,532

-

-27,860

-55,780

-29,432

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-74

12,591

-32,312

-24,805

-29,406

-8,720

-27,570

-24,970

-17,416

-16,894

-11,355

-16,377

-17,021

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-10,344

-3,149

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

4,263

3,947

4,474

-

4,393

3,689

4,805

-

147

107

114

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

-

-

-

-

-

-

-

-

-

-

-

457

10

15

15

570

14

21

18

32

15

15

14

18

7

7

5

18

Non-cash interest expense

-

-4,679

-3,230

-

-

-6,271

-5,954

-917

-1,676

-1,343

-1,155

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Allocated Share-based Compensation Expense

-687

1,315

892

-576

1,668

1,418

955

4,822

548

508

572

-5,003

2,478

2,675

2,365

-2,642

1,566

1,426

1,435

-

-

-

-

-

-

-

-

-

Issuance of common shares for service

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Issuance of common shares for license agreement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Share-based compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

663

730

876

-

861

628

990

164

Change in fair value of warrant & conversion liabilities

-

-

-6,015

-

-

-

-24,085

0

-701

311

55

-

-

-

-

-

-

-

-

-0

-0

-75

-44

-

-

-

-

-

Loss on disposal of assets

-

-

-

-

-

-

-

-

28

-33

-9

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of debt issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

15

14

15

-

34

187

184

192

171

185

217

-

-

-

-

-

Loss on extinguishment of debt

-2,692

0

-346

0

0

0

-2,595

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Reversal of loss contract

-914

122

792

0

5,330

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrant liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-87

Amortization of debt issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

237

106

88

94

Changes in operating assets and liabilities:
Receivables

-148

4,189

-7,593

-16,419

18,294

-2,699

5,868

-3,931

3,246

1,202

2,623

3,065

500

185

-3,793

-520

-596

-10,524

11,868

-1,238

2,253

-1,809

1,519

-

-

-

-

-

Inventory

-2,806

-2,033

3,093

6,669

6,244

2,626

2,002

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets and liabilities

3,985

-970

1,551

-2,494

833

-1,812

1,293

322

-288

544

-1,178

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses

-

-

-

-

-

-

-

-

-

-

-

-

-531

82

668

-

-416

-726

-870

-333

756

1,194

1,361

83

-187

-131

378

671

Deposits

-

-

-

-

-

-

-

-

-

-

-

-

-72

66

79

-

-

-

-

-0

-35

35

12

10

0

0

0

0

Accounts payable

3,127

-2,529

-8,372

503

3,150

649

3,983

-8,572

3,868

2,093

1,342

-2,917

-2,003

3,342

1,557

-5,899

1,165

2,902

-1,042

1,132

1,358

615

2,513

-

-

-

-

-

Accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,914

365

-563

-330

Accrued expenses

-2,654

5,106

-9,711

8,457

-5,689

3,494

-4,817

7,736

2,060

196

2,022

-2,455

858

239

-482

-2,886

694

252

-478

180

417

-57

70

-31

-456

-119

656

433

Accrued interest on notes payable

258

-135

-46

97

0

4,389

-284

9

254

-133

-20

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued payroll and benefits

-

-

-

-

-

-

-

-

-

-

-

-

1,453

1,175

-1,286

-

725

667

-1,032

302

436

443

-629

328

248

254

-392

-234

Other non-current assets and liabilities

-4,836

702

-2,256

2,948

103

-2,495

1,930

-616

-49

343

165

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-26,822

-25,676

-37,321

-

-64,961

-54,330

-51,419

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-9,937

-3,761

Investing activities
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

3,565

672

-29,398

-17,678

-24,176

-13,042

-22,207

-7,976

-29,329

-13,186

-5,068

-13,941

-16,895

-

-

-

-

-

IDB acquisition

0

0

0

-1

0

0

166,383

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of intangible assets

0

0

1,209

0

0

2,000

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of property and equipment

0

0

12

247

516

423

504

58

198

484

109

-

-

-

-

642

0

0

46

15

0

15

21

83

8

23

18

4

Proceeds from borrowing on convertible promissory notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Proceeds from borrowing on long-term debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

5,238

0

0

Purchase of investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Proceeds from sale of investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net cash used in investing activities

0

0

-1,221

-

-516

-2,423

-166,887

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-18

-4

Financing activities
Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-109

-

-

-

-

-642

0

0

-46

-15

0

-15

-21

-

-

-

-

-

Proceeds from the issuance of notes payable

0

0

0

0

0

0

111,421

-1,156

10,000

21,990

8,010

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the issuance of convertible notes payable to related party

0

0

75,000

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

702

Proceeds from issuance of common stock upon private placement, net of underwriting discounts

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Payment of share issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Costs associated with the issuance of notes payable

0

882

1,301

0

0

0

6,455

-

-

-

-

-

-

-

-

-

-

-

-

0

0

1

33

0

0

300

0

0

Proceeds from the issuance of warrants

0

0

0

0

0

0

33,264

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the issuance of royalty agreement

0

0

0

0

0

0

1,472

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of notes payable disbursement option

0

0

0

0

0

0

7,609

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options and warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

695

1,709

549

-

-

-

-

-

-

-

-

-

Proceeds from Issuance of Common Stock

0

0

0

0

0

0

51,452

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock, net

0

0

8

0

-486

115,759

40,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Debt extinguishment

0

0

0

0

0

0

2,150

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

IDB acquisition deferred payments

0

0

72

906

329

398

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the exercise of stock options, net of cancellations

0

0

0

0

0

0

3

-7

0

0

95

-299

31

94

239

-

-

-

-

-

79

46

2

-

-

-

0

0

Proceeds from the issuance of convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Proceeds from issuance of common stock, net of underwriting discounts

-

-

-

-

-

-

-

-

-

-

-

-

29,208

45,904

94,000

-

0

0

139,044

-

-

-

-

0

-34

54,442

0

54,777

Payment of preferred stock issuance costs

-

-

-

-

-

-

-

-

-

-

-

-275

0

65

219

-121

0

0

213

-

-

-

-

-

-

-

-

-

Principal payments on notes payable

0

0

0

-

0

0

40,000

-

0

21,659

2,844

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

5,261

-114,119

27,571

44,822

94,020

-49,603

1,816

1,266

139,380

38,141

10,598

3,045

-31

-

-

-

-

-

Net cash provided by financing activities

0

-882

73,635

-

-815

115,361

181,398

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

54,075

Net decrease in cash and equivalents

-26,822

-26,558

35,093

-

-66,292

58,608

-36,908

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net change in cash and equivalents

-

-

-

-

-

-

-

-

-

-

8,717

-113,901

-1,827

27,135

69,844

-63,287

-20,391

-6,710

110,005

24,940

5,530

-10,912

-16,948

-13,900

-11,228

61,479

-9,956

50,308

Supplemental cash flow information:
Cash paid for interest

4,305

4,276

4,486

0

8,779

0

4,480

950

-491

1,379

488

1,495

291

303

322

374

357

439

430

434

420

366

358

362

447

159

238

206

Supplemental disclosure of non-cash financing and investing activities:
Accrued purchases of fixed assets

0

-12

12

-

-137

39

327

-

-97

56

56

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued notes payable issuance costs

-

-

-

-

-

-

-

-

-

-

479

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of redeemable convertible preferred shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

313

Beneficial conversion costs of Series B preferred shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Notes payable converted into Series A redeemable convertible preferred shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Allocation of the Class C proceeds to the Class C Purchase Option

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Conversion of the Class C Purchase Option

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Allocation of the convertible note proceeds to warrant

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Allocation of the long-term debt proceeds to warrant

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

461

0

0

Conversion of convertible notes payable and accrued interest into common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

4,724

Conversion of redeemable convertible preferred shares into common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

94,827

Reclassification of warrant liability to additional paid-in capital

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

1,033